QualityStocksNewsBreaks Archives - Page 597 of 1512

WednesdayDec 22, 2021 1:50 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Scalable UST(TM) Process Shown to Create Rock-Solid 18-Month Stability

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and innovative services to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, agrochemical, and food and beverage industries. The company today announced that hemp-derived cannabidiol (“CBD”) processed with its patented Ultra Shear Technology(TM) (“UST(TM)”) platform produced high-quality water-soluble nanoemulsions of CBD oil in water that have demonstrated rock-solid visual and analytical stability 18 months after production and baseline testing. “Nanoemulsions, liposomes and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or…

WednesdayDec 22, 2021 12:48 pm

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Lauded for Impressive Expertise Across Multiple Sectors

SRAX (NASDAQ: SRAX) is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients, valuable to marketing and communications. Its flagship offering is a premier investor intelligence and communications platform branded Sequire. SRAX also recently launched an IR Website Builder, SMS feature and VIRA, and an IR chatbot, expanding its offering and translating to a strong increase in revenue. “SRAX’s technology unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and…

WednesdayDec 22, 2021 12:37 pm

QualityStocksNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Committed to Creating World’s Largest Rapid Testing Network in Pharmacy

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a point-of-care health testing technology innovator, has rolled out its trademarked HealthTab(TM) platform in select Ontario and British Columbia Shoppers Drug Mart network pharmacies. The company continues to add lab-accurate test functionality to its kiosks, most recently announcing a solution for monitoring kidney function. Already, Avricore has agreements with Abbott Laboratories currently in the pilot stage that allow for the testing of markers related to conditions such as diabetes, heart disease and viruses such as SARS-CoV-2, RSV, influenza A and B, and strep, empowering patients who want to take a greater role in managing…

WednesdayDec 22, 2021 12:02 pm

QualityStocksNewsBreaks – SPYR Inc.’s (SPYR) Applied Magix TV Commercials Complete, Scheduled to Air

SPYR (OTCQB: SPYR) (dba SPYR Technologies) is a technology company whose subsidiary, Applied Magix Inc., develops and resells Apple(R) ecosystem compatible products in the growing multibillion IoT smart home and connected car markets. The company has announced completion of the production of its TV commercials and that the initial round of 30- and 60-second commercials is scheduled for airing. According to the update, TVA Media Group (“TVA”) has booked a set of test airings of the commercials to occur during the week of Dec. 27, 2021. TVA projects that the commercials will be seen by more than one million viewers…

WednesdayDec 22, 2021 11:42 am

QualityStocksNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Partners with Avicanna to Launch New Derma-Cosmetic Brand

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, is working with Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) to unveil a new THC-free, CBD derma-cosmetic brand. The first known CBD skincare line to be clinically tested and commercialized across four international markets, Pura H&W will include seven SKUs of proprietary products. The products are formulated using a combination of purified CBD and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura H&W product line was developed by Avicanna and specific products have undergone clinical trials.…

WednesdayDec 22, 2021 11:05 am

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with Maya. The two companies plan to co-develop a novel digital therapeutics (DTx) platform, which would allow Mydecine to enhance treatment effectiveness by pairing the DTx with its existing digital health platform, Mindleap Health, alongside its medication-based treatments to create a trifecta approach. “The technology integration of the two software platforms is aimed at enhancing Mindleap’s medical capabilities to more quickly and efficiently develop a personalized prescription-based digital…

WednesdayDec 22, 2021 10:50 am

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Names New CEO

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) has appointed a Global CPG veteran as its new CEO. Marc Aneed, who has been serving as Eat Well’s president and director, is replacing David Doherty, who is retiring. Aneed has more than two decades of experience with some of the world’s most renowned CPG brands including PepsiCo, Quaker Oat and Gatorade. He has led many iconic consumer brands and managed an estimated $1 billion growth across dozens of product categories. Most recently, Aneed was at Glanbia PLC, a global nutrition company where he led the company’s Amazing Grass division. Aneed has…

WednesdayDec 22, 2021 9:55 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months,” said Cybin’s CEO Doug Drysdale in…

TuesdayDec 21, 2021 3:40 pm

QualityStocksNewsBreaks – Friendable Inc. (FDBL) CEO Featured in Magazine Article with 90 Million+ Reach

Friendable (OTC: FDBL) CEO Robert A. Rositano Jr. is spotlighted in a recent Authority Magazine article. The article, titled “5 Things I Wish Someone Had Told Me Before I Became a Founder,” shared insights from Rositano, who is also the founder of Friendable, a mobile technology and marketing company. Authority Magazine is a Medium publication devoted to sharing interesting “interview series” featuring people recognized as professionals and experts in business, film, sports and tech. In the article, Rositano shares insights that could help others avoid costly mistakes; he also discusses the company’s plans to expand its flagship Fan Pass service,…

TuesdayDec 21, 2021 2:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies that evidenced effective, sustained and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approvals for the protocols around its fourth hypertension study, HYPER-H21-4, which is just one of the many planned studies slated for 2022. “Others include HOR-A22-1, a pharmacokinetic study…

Site Search

Company Search

Category: QualityStocksNewsBreaks